Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer: a working hypothesis.

Systematic analysis of copy number variants of a large cohort of orofacial cleft patients identifies candidate genes for orofacial clefts. Hum Genet (2015) 0.77

Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04

Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res (2004) 5.13

sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell (1998) 4.40

Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development (1999) 3.84

Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol (2002) 3.35

Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34

Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell (2005) 2.95

Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res (2003) 2.91

Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Dev Cell (2005) 2.84

Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol (2003) 2.71

Sprouty, an intracellular inhibitor of Ras signaling. Cell (1999) 2.51

Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48

Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res (2005) 2.44

The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer (2004) 1.86

Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res (1999) 1.80

Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr Biol (1999) 1.75

sprouty4 acts in vivo as a feedback-induced antagonist of FGF signaling in zebrafish. Development (2001) 1.64

The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res (2004) 1.54

Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res (2007) 1.52

Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res (2006) 1.52

The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res (2004) 1.51

Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. J Biol Chem (2001) 1.46

Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol (2007) 1.46

Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology (2008) 1.35

Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene (2006) 1.34

Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene (2007) 1.28

The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem (2005) 1.28

Human prostate cancer precursors and pathobiology. Urology (2003) 1.27

Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia (2008) 1.26

The economic burden of prostate cancer. BJU Int (2011) 1.23

Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. J Biol Chem (2003) 1.22

Expression of sprouty2 during early development of the chick embryo is coincident with known sites of FGF signalling. Mech Dev (2000) 1.14

Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer (2006) 1.12

Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. Cancer Res (2010) 1.04

Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesis. Am J Respir Cell Mol Biol (2008) 1.00

Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-beta1. Prostate (2004) 0.99

Sprouty is a negative regulator of transforming growth factor β-induced epithelial-to-mesenchymal transition and cataract. Mol Med (2012) 0.95

Sprouty genes function in suppression of prostate tumorigenesis. Proc Natl Acad Sci U S A (2012) 0.93

An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer (2001) 0.92

Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer. Br J Cancer (2012) 0.82

Sprouty1 induces a senescence-associated secretory phenotype by regulating NFκB activity: implications for tumorigenesis. Cell Death Differ (2013) 0.79

Non-essential role for cilia in coordinating precise alignment of lens fibres. Mech Dev (2016) 0.75